reports
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
Inventiva to Participate in Four Upcoming March Investor Conferences
Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...
Inventiva participera à quatre conférences investisseurs en mars
Inventiva participera à quatre conférences investisseurs en mars Daix (France), New York (États-Unis), le 26 février 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que la direction de la Société participera à des réunions individuelles et à des présentations lors des événements investisseurs suivants : TD Cowen 46ème Health Care Conference – 2 au 4 mars 2026Date : lun...
Inventiva to Participate in Four Upcoming March Investor Conferences
Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...
Inventiva to Participate in Four Upcoming March Investor Conferences
Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2...
- Konrad Zomer
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SK SEB SA
ADEN ADECCO GROUP AG
AGS AGEAS SA/NV
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
EOAN E.ON SE
ELE ENDESA S.A.
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
EDW EDP RENOVAVEIS SA
MONC MONCLER SPA
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
LDO LEONARDO SPA
ALC ALCON INC.
BEAN BELIMO HOLDING AG
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- Konrad Zomer
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SK SEB SA
ADEN ADECCO GROUP AG
AGS AGEAS SA/NV
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
EOAN E.ON SE
ELE ENDESA S.A.
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
EDW EDP RENOVAVEIS SA
MONC MONCLER SPA
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
LDO LEONARDO SPA
ALC ALCON INC.
BEAN BELIMO HOLDING AG
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- ING Helpdesk
Benelux Morning Notes
Ageas: Upgrading net op. result FY26 target to >€1.5bn from €1.35bn in FY25 as M&A starts contributing / CFE: Strong 2H, flips to net cash and outlook better / Deceuninck: FY25 results in line with expectations, Türkiye a tad better / GBL: Exits Umicore fully / Vopak: Five-year SBB programme announced / Wolters Kluwer: 2025 roughly in line, good 2026 outlook
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
Ageas reports full-year 2025 results
Ageas reports full-year 2025 results Regulated information • Brussels, 25 February 2026 • 7:30am (CET) Ageas reports full-year 2025 results Strong performance in a transformational year for Ageas INFLOWS NETOPERATINGRESULT HOLDING FREE CASH FLOW GROSS DIVIDEND 2025EUR 19.6 billion EUR 1.65 billion EUR 774 million EUR 3.75+9% vs 2024 +33% vs 2024 +19% vs 2024 +7% vs 2024 A complete overview of the figures and comparison with previous year can be found on page 7 of this press release and on the Ageas website. Hans De Cuyper, CEO Ageas, comments: “2025 was a landmark year for Ageas - a yea...
Ageas publie ses résultats pour l’exercice 2025
Ageas publie ses résultats pour l’exercice 2025 Informations réglementées • Bruxelles, le 25 février 2026 – 7h30 (CET) Ageas publie ses résultats pour l’exercice 2025Solide performance au cours d’une année de transformation ENCAISSEMENTS RÉSULTATOPÉRATIONNELNET HOLDINGFREE CASH FLOW DIVIDENDEBRUT2025EUR 19,6 milliards EUR 1,65 milliard EUR 774 millions EUR 3,75+9% vs 2024 +33% vs 2024 +19% vs 2024 +7% vs 2024 Un aperçu des chiffres et une comparaison avec l’année précédente sont disponibles à la page 8 de ce communiqué de presse et sur le site web d’Ageas. Hans De Cuyper, CEO d’Ageas, a d...
Ageas rapporteert resultaten over 2025
Ageas rapporteert resultaten over 2025 Gereglementeerde informatie • Brussel, 25 februari 2026 • 7u30 (CET) Ageas rapporteert resultaten over 2025Sterke resultaten in een jaar van transformatie voor Ageas PREMIE-INKOMEN NETTOOPERATIONEELRESULTAAT HOLDING FREE CASH FLOW BRUTO DIVIDEND 2025EUR 19,6 miljard EUR 1,65 miljard EUR 774 miljoen EUR 3,75+9% vs 2024 +33% vs 2024 +19% vs 2024 +7% vs 2024 Een overzicht van de cijfers en een vergelijking met vorig jaar is te vinden op pagina 8 van dit persbericht en op de website van Ageas. Hans De Cuyper, CEO Ageas, zei: “2025 was een mijlpaal voor A...
Barco NV: 1 director
A director at Barco NV bought 849,270 shares at 10.980EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- ING Helpdesk
Benelux Morning Notes
AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...
PROX PROXIMUS SA DE DROIT PUBLIC
KPN ROYAL KPN NV
BAMNB KONINKLIJKE BAM GROEP NV
AF AIR FRANCE-KLM SA
GIMB GIMV NV
ARCAD ARCADIS NV
ASC ASCENCIO SCA
VGP VGP NV
KIN KINEPOLIS GROUP NV
OBEL ORANGE BELGIUM SA
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
AZE AZELIS GROUP NV
AGN AEGON N.V.
MICC MAGNUM ICE CREAM COMPANY N.V. (THE)
- Maxime Kogge
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
FHZN FLUGHAFEN ZURICH AG
ISP INTESA SANPAOLO S.P.A.
UCG UNICREDIT S.P.A.
NN NN GROUP N.V.
CLNX CELLNEX TELECOM S.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
CCEP COCA-COLA EUROPEAN PARTNERS PLC
IHG INTERCONTINENTAL HOTELS GROUP PLC
CPR DAVIDE CAMPARI-MILANO N.V.
- Maxime Kogge
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
FHZN FLUGHAFEN ZURICH AG
ISP INTESA SANPAOLO S.P.A.
UCG UNICREDIT S.P.A.
NN NN GROUP N.V.
CLNX CELLNEX TELECOM S.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
IHG INTERCONTINENTAL HOTELS GROUP PLC
CPR DAVIDE CAMPARI-MILANO N.V.
- Mathijs Geerts Danau
Inventiva FIRST LOOK: preliminary FY25 results hold no surprises
Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.
- Guy Sips
- Mathijs Geerts Danau
- Wim Hoste
Inventiva reports preliminary 2025¹ fiscal year financial results
Inventiva reports preliminary 2025¹ fiscal year financial results Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the developmen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.